Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | +6.13% | -13.46% | -66.59% |
Financials (USD)
Sales 2024 * | 25.22M | Sales 2025 * | 32.65M | Capitalization | 3.14M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -9M | EV / Sales 2024 * | 0.12 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.1 x |
P/E ratio 2024 * |
-0.14
x | P/E ratio 2025 * |
-0.59
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | +6.13% | ||
1 week | -13.46% | ||
Current month | +4.65% | ||
1 month | -5.06% | ||
3 months | -60.39% | ||
6 months | -78.87% | ||
Current year | -66.59% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 17 M€ | +5.10% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 2.25 | +6.13% | 2,240 |
24-05-14 | 2.12 | -5.78% | 404 |
24-05-13 | 2.25 | -0.99% | 15,120 |
24-05-10 | 2.272 | +1.00% | 1,301 |
24-05-09 | 2.25 | -13.46% | 11,869 |
Delayed Quote OTC Markets, May 15, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.59% | 3.14M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- EIGR Stock